Patents by Inventor Libo Wu
Libo Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9119238Abstract: A method for driving an LED connected to a power switch is provided. The method includes: determining a duty cycle of a pulse sequence for controlling the power switch according to a present current and a predetermined operating current of the LED; generating the pulse sequence according to the duty cycle and according to at least one of a randomized period sequence and a randomized pulse position sequence; and controlling switching operation of the power switch by the pulse sequence, so as to drive the LED. An apparatus for driving a light emitting diode, an apparatus for dimming a light emitting diode and illumination systems are also provided.Type: GrantFiled: August 26, 2011Date of Patent: August 25, 2015Assignee: OSRAM GmbHInventors: Yang Hu, LiBo Wu
-
Publication number: 20150190510Abstract: The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.Type: ApplicationFiled: February 5, 2015Publication date: July 9, 2015Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul DALVI, Libo WU
-
Publication number: 20150133456Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: January 9, 2015Publication date: May 14, 2015Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20150038525Abstract: Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT2B receptor without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein such as, for example, are methods of agonizing the 5-HT1A receptor using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 22, 2014Publication date: February 5, 2015Inventors: Libo WU, Jian ZHANG
-
Publication number: 20140377189Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a stable solution formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).Type: ApplicationFiled: June 18, 2014Publication date: December 25, 2014Inventors: Libo WU, Wiwik WATANABE
-
Publication number: 20140377365Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).Type: ApplicationFiled: June 18, 2014Publication date: December 25, 2014Inventors: Libo WU, Wiwik WATANABE
-
Patent number: 8895743Abstract: Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT2B receptor without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein such as, for example, are methods of agonizing the 5-HT1A receptor using the compounds and compositions disclosed herein.Type: GrantFiled: December 19, 2013Date of Patent: November 25, 2014Assignee: Map Pharmaceuticals, Inc.Inventors: Libo Wu, Jian Zhang
-
Publication number: 20140247563Abstract: A driver assembly includes a driver housing and a driver, the driver including at least one first portion and a second portion, the first portion having a lower heat resistance than the second portion, wherein the driver housing includes at least one first cavity for at least partially accommodating the first portion and a second cavity for accommodating the second portion, and a potting material is potted into the first cavity to envelop the first portion.Type: ApplicationFiled: October 10, 2012Publication date: September 4, 2014Inventors: MingTao Wang, Guoan He, LiBo Wu
-
Publication number: 20140229957Abstract: The present invention provides a multi-core processor system, including: multiple central processor units and multiple groups of level-one hardware message queues. Each central processor unit is separately connected to a group of level-one hardware message queues and is configured to process messages in the level-one hardware message queues. Each group of level-one hardware message queues includes multiple level-one hardware message queues. Moreover, in each group of level-one hardware message queues, a level-one hardware message queue having a higher priority is scheduled preferentially, and level-one hardware message queues having the same priority are scheduled in a round-robin manner according to round robin scheduling weights. Through the multi-core processor system provided in the present invention, the efficiency and performance of the multi-core processor system are improved.Type: ApplicationFiled: April 28, 2014Publication date: August 14, 2014Applicant: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Weiguo Zhang, Libo Wu
-
Publication number: 20140179705Abstract: 8?-Hydroxy-Dihydroergotamine (8?-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140179707Abstract: Provided herein are 8?-Hydroxy-2-CF3-dihydroergotamine (8?OH-2-CF3-DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140179706Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140179730Abstract: Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT2B receptor without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein such as, for example, are methods of agonizing the 5-HT1A receptor using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Libo Wu, Jian Zhang
-
Publication number: 20140120165Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: ApplicationFiled: October 2, 2013Publication date: May 1, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo Wu, Wiwik Watanabe, Jian Zhang
-
Patent number: 8586007Abstract: The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.Type: GrantFiled: October 20, 2008Date of Patent: November 19, 2013Assignee: Wayne State UniversityInventors: Sandro R. P. Da Rocha, Libo Wu
-
Patent number: 8574630Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: GrantFiled: September 20, 2011Date of Patent: November 5, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Libo Wu, Wiwik Watanabe, Jian Zhang
-
Publication number: 20130154500Abstract: A method for driving an LED connected to a power switch is provided. The method may include: determining a duty cycle of a pulse sequence for controlling the power switch according to a present current and a predetermined operating current of the LED; generating the pulse sequence according to the duty cycle and according to at least one of a randomized period sequence and a randomized pulse position sequence; and controlling switching operation of the power switch by the pulse sequence, so as to drive the LED.Type: ApplicationFiled: August 26, 2011Publication date: June 20, 2013Applicant: OSRAM AGInventors: Yang Hu, LiBo Wu
-
Publication number: 20120135046Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: ApplicationFiled: September 20, 2011Publication date: May 31, 2012Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo WU, Wiwik WATANABE, Jian ZHANG
-
Publication number: 20120067343Abstract: Described here are compositions and methods for the treatment of respiratory conditions using glucocorticosteroids delivered by a next generation nebulizer. The methods administer a therapeutic dose with nebulization time of 2 minutes or less. The faster nebulization time improves patient compliance.Type: ApplicationFiled: September 20, 2011Publication date: March 22, 2012Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo WU, Wiwik WATANABE
-
Publication number: 20110223216Abstract: The subject matter disclosed herein relates to compositions and methods for engineering porous particles for aerosol formulations for pulmonary drug delivery. Certain embodiments disclosed herein further relate to methods for stabilizing suspension-based formulations in hydrofluoroalkane propellants with nanoparticles.Type: ApplicationFiled: November 17, 2009Publication date: September 15, 2011Applicant: WAYNE STATE UNIVERSITYInventors: Sandro R.P. Da Rocha, Libo Wu